Barclays Keeps Their Hold Rating on Blueprint Medicines (BPMC)
Barclays analyst Peter Lawson maintained a Hold rating on Blueprint Medicines (BPMC – Research Report) today and set a price target of $105.00.
Fintel on MSN22h
Barclays Downgrades Illumina (ILMN)
Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to Underweight. Analyst Price Forecast Suggests 49.02% Upside As of January ...
Illumina downgraded to Underweight from Equal Weight at Barclays
Barclays downgraded Illumina (ILMN) to Underweight from Equal Weight.Maximize Your Portfolio with Data Driven Insights:Leverage the power of ...
£10,000 invested in Barclays shares 1 month ago is now worth…
Barclays shares have carried on where they left off in 2024, by climbing far faster than the FTSE 100. Harvey Jones wonders ...
FTSE 100 forecast ahead of Barclays, Unilever, BAT, Coca-Cola earnings
This article looks at the FTSE 100 index and what to expect next week as several blue chip companies like Barclays and ...